Table 1 Currently active or planned trials incorporating AGuIX, as of June 2022

NANORAD-2, France

Phase II recruiting

CNS metastases

Whole-brain radiotherapy plus AGuIX (experimental group) vs whole-brain radiotherapy alone

3 injections of AGuIX given, within 7 days of commencement of therapy, before 1st fraction and before 6th fraction, in experimental arm

NANOCOL, France

Phase I recruiting

Locally advanced cervical cancer

AguIX (up to 50 mg/kg) plus cisplatin plus external beam radiotherapy plus brachytherapy

AGuIX delivered on 1st and 11th days of radiotherapy. MRI performed after AGuIX

NANOSMART

Phase I/II recruiting

Lung cancer and pancreatic cancer

Stereotactic radiotherapy plus AGuIX vs stereotactic radiotherapy alone

AGuIX given 7 or 14 days before radiotherapy, then with 1st fraction and 4th fraction in those with radiation over 2 weeks

Both groups receive MRI-guided stereotactic radiotherapy

NANOBRAINMETS, United States

Phase II recruiting

CNS metastases

Stereotactic radiotherapy plus AGuIX, vs stereotactic radiotherapy plus placebo

Experimental arm will receive AGuIX 3–5 days before irradiation, before first fraction, and on third day of irradiation if more than 4 days of radiation therapy

NANO-GBM

Phase I/II recruiting

Glioblastoma multiforme

60 Gy radiation therapy plus AGuIX plus chemotherapy (temozolomide) vs 60 Gy radiation without AGuIX plus chemotherapy (temozolomide)

Radiotherapy delivered as 60 Gy over 6 weeks, with four injections of AGuIX